Veradermics, Incorporated Cash Flow-to-Debt Ratio
Veradermics, Incorporated cash flow-to-debt ratio. Veradermics, Incorporated (MANE) has a Cash Flow-to-Debt Ratio of -3.15x as of March 2026, meaning its operating cash flow of $-21.17 Million could theoretically repay -3% of its total liabilities ($6.72 Million) in one year. See Veradermics, Incorporated (MANE) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Veradermics, Incorporated (2023–2025)
Cash flow-to-debt ratio of Veradermics, Incorporated from 2023 to 2025. Historical debt coverage capacity for Veradermics, Incorporated across 3 annual periods. Also explore MANE net assets growth trend to track the company's year-over-year net asset growth rate.
Veradermics, Incorporated Cash Flow-to-Debt Ratio by Year (2023–2025)
Veradermics, Incorporated cash flow-to-debt ratio by year from 2023 to 2025. Year-by-year debt coverage analysis for Veradermics, Incorporated. For the full cash flow conversion analysis, see Veradermics, Incorporated cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.26x | $-71.60 Million | $273.63 Million | ▲ +94.8% |
| 2024 | -5.02x | $-23.69 Million | $4.72 Million | ▼ -42.6% |
| 2023 | -3.52x | $-13.51 Million | $3.84 Million | — |